Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA)

Trial Profile

Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs Ubenimex (Primary)
  • Indications Lymphoedema
  • Focus Therapeutic Use
  • Acronyms ULTRA
  • Sponsors Eiger BioPharmaceuticals
  • Most Recent Events

    • 04 Jan 2018 According to an Eiger BioPharmaceuticals media release, enrollment in this trial has been completed and results are expected in second half of 2018.
    • 28 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Nov 2017 According to an Eiger BioPharmaceuticals media release, the company anticipates to complete the trial in 2H 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top